Market Overview:
The global cancer immunotherapy drugs market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for novel and targeted therapies, and growing focus on personalized medicine. The global cancer immunotherapy drugs market is segmented on the basis of type into monoclonal antibodies, check point inhibitors, interferons, and interleukins. The monoclonal antibody segment is expected to account for the largest share of the global cancer immunotherapy drugs market in 2018. This segment is projected to grow at a CAGR of 11% during the forecast period from 2018 to 2030. The large share of this segment can be attributed to factors such as increasing use of monoclonal antibodies for targeted therapy and rising prevalence of cancers that are susceptible to these therapies. On the basis application, lung cancer accounted for majority share in 2017 owing high mortality rate associated with it across all regions followed by liver & colorectal cancers respectively .
Product Definition:
Cancers Immunotherapy Drugs are drugs that work to help the body's immune system fight cancer. Immunotherapy drugs can be used on their own or in combination with other treatments, such as chemotherapy or radiation therapy. The importance of immunotherapy drugs is that they can attack cancer cells directly and also help the body's natural defenses work better to fight the cancer.
Monoclonal Antibodies:
Monoclonal antibodies are antibody molecules that are manufactured by the body's immune system to fight off infections and cancer. The most common types of monoclonal antibodies used in oncology therapeutics include humanized, chimeric, and fully human monoclonal antibodies.
Check Point Inhibitors:
Check point inhibitors are a type of medication that blocks the action of some Checkpoints which are used by the immune system to protect cancer cells from being attacked by the body's own immune system. The main function of check points is to avoid collateral damage to healthy tissues during immunotherapy treatment. Some common types of check points inhibitors include PD-1, CTLA-4 and IP-10.
Application Insights:
The lung cancer segment dominated the global market in 2017. This can be attributed to the rising prevalence of smoking and other forms of tobacco consumption globally. For instance, as per the World Health Organization (WHO), around 1 billion people smoke globally, which is approximately 15% of total population. Moreover, an estimated 6 million deaths occur due to lung cancer every year worldwide.
In addition, a large number of clinical trials are ongoing for various types of immunotherapy drugs for treating different types of lung cancers at various stages including pre-clinical testing phase and actual treatment stage. For instance, Keytruda (pembrolizumab) is being studied in several Phase III clinical trials for non-small cell Lung Cancer (NSCLC). The drug is currently under review by U.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and Celgene Corporation; in this region. The U.S.-based companies are engaged in extensive R&D activities for the development of immunotherapy drugs for use against cancers worldwide. These companies have established a strong distribution network across North America and Europe that enables them to monitor product developments and commercialize their products at an early stage.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising incidences of cancer among people coupled with increasing disposable income levels, especially in emerging countries like China and India (Bharat).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the global immunotherapy drugs market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This high incidence rate is expected to drive demand for immunotherapy drugs over the forecast period.
- Rising prevalence of lifestyle-associated diseases: The rising prevalence of lifestyle-associated diseases such as obesity and diabetes is also contributing to the growth of the global immunotherapy drugs market as these diseases are known to increase susceptibility to various types of cancers. For instance, according to a study published by JAMA Oncology in 2016, obesity increases risk for 13 types cancers including breast cancer, colorectal cancer, and pancreatic cancer.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancers Immunotherapy Drugs Market Research Report
By Type
Monoclonal Antibodies, Check Point Inhibitors, Interferons, Interleukins
By Application
Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Other Cancers
By Companies
Roche, Pfizer, Merck, Novartis, Johnson & Johnson, Sanofi, GlaxoSmithKline, Amgen, AbbVie, Boehringer Ingelheim, AstraZeneca, Immatics Biotechnologies
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
174
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Cancers Immunotherapy Drugs Market Report Segments:
The global Cancers Immunotherapy Drugs market is segmented on the basis of:
Types
Monoclonal Antibodies, Check Point Inhibitors, Interferons, Interleukins
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Other Cancers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Pfizer
- Merck
- Novartis
- Johnson & Johnson
- Sanofi
- GlaxoSmithKline
- Amgen
- AbbVie
- Boehringer Ingelheim
- AstraZeneca
- Immatics Biotechnologies
Highlights of The Cancers Immunotherapy Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Check Point Inhibitors
- Interferons
- Interleukins
- By Application:
- Lung Cancer
- Liver Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Breast Cancer
- Other Cancers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancers Immunotherapy Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancers Immunotherapy Drugs are medications that help the bodyu2019s immune system fight cancer.
Some of the key players operating in the cancers immunotherapy drugs market are Roche, Pfizer, Merck, Novartis, Johnson & Johnson, Sanofi, GlaxoSmithKline, Amgen, AbbVie, Boehringer Ingelheim, AstraZeneca, Immatics Biotechnologies.
The cancers immunotherapy drugs market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancers Immunotherapy Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancers Immunotherapy Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancers Immunotherapy Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancers Immunotherapy Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancers Immunotherapy Drugs Market Size & Forecast, 2018-2028
4.5.1 Cancers Immunotherapy Drugs Market Size and Y-o-Y Growth
4.5.2 Cancers Immunotherapy Drugs Market Absolute $ Opportunity
Chapter 5 Global Cancers Immunotherapy Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cancers Immunotherapy Drugs Market Size Forecast by Type
5.2.1 Monoclonal Antibodies
5.2.2 Check Point Inhibitors
5.2.3 Interferons
5.2.4 Interleukins
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cancers Immunotherapy Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cancers Immunotherapy Drugs Market Size Forecast by Applications
6.2.1 Lung Cancer
6.2.2 Liver Cancer
6.2.3 Colorectal Cancer
6.2.4 Pancreatic Cancer
6.2.5 Breast Cancer
6.2.6 Other Cancers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancers Immunotherapy Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancers Immunotherapy Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cancers Immunotherapy Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Cancers Immunotherapy Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cancers Immunotherapy Drugs Market Size Forecast by Type
9.6.1 Monoclonal Antibodies
9.6.2 Check Point Inhibitors
9.6.3 Interferons
9.6.4 Interleukins
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cancers Immunotherapy Drugs Market Size Forecast by Applications
9.10.1 Lung Cancer
9.10.2 Liver Cancer
9.10.3 Colorectal Cancer
9.10.4 Pancreatic Cancer
9.10.5 Breast Cancer
9.10.6 Other Cancers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cancers Immunotherapy Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Cancers Immunotherapy Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cancers Immunotherapy Drugs Market Size Forecast by Type
10.6.1 Monoclonal Antibodies
10.6.2 Check Point Inhibitors
10.6.3 Interferons
10.6.4 Interleukins
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cancers Immunotherapy Drugs Market Size Forecast by Applications
10.10.1 Lung Cancer
10.10.2 Liver Cancer
10.10.3 Colorectal Cancer
10.10.4 Pancreatic Cancer
10.10.5 Breast Cancer
10.10.6 Other Cancers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cancers Immunotherapy Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cancers Immunotherapy Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cancers Immunotherapy Drugs Market Size Forecast by Type
11.6.1 Monoclonal Antibodies
11.6.2 Check Point Inhibitors
11.6.3 Interferons
11.6.4 Interleukins
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cancers Immunotherapy Drugs Market Size Forecast by Applications
11.10.1 Lung Cancer
11.10.2 Liver Cancer
11.10.3 Colorectal Cancer
11.10.4 Pancreatic Cancer
11.10.5 Breast Cancer
11.10.6 Other Cancers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cancers Immunotherapy Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Cancers Immunotherapy Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cancers Immunotherapy Drugs Market Size Forecast by Type
12.6.1 Monoclonal Antibodies
12.6.2 Check Point Inhibitors
12.6.3 Interferons
12.6.4 Interleukins
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cancers Immunotherapy Drugs Market Size Forecast by Applications
12.10.1 Lung Cancer
12.10.2 Liver Cancer
12.10.3 Colorectal Cancer
12.10.4 Pancreatic Cancer
12.10.5 Breast Cancer
12.10.6 Other Cancers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cancers Immunotherapy Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cancers Immunotherapy Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cancers Immunotherapy Drugs Market Size Forecast by Type
13.6.1 Monoclonal Antibodies
13.6.2 Check Point Inhibitors
13.6.3 Interferons
13.6.4 Interleukins
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cancers Immunotherapy Drugs Market Size Forecast by Applications
13.10.1 Lung Cancer
13.10.2 Liver Cancer
13.10.3 Colorectal Cancer
13.10.4 Pancreatic Cancer
13.10.5 Breast Cancer
13.10.6 Other Cancers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancers Immunotherapy Drugs Market: Competitive Dashboard
14.2 Global Cancers Immunotherapy Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Pfizer
14.3.3 Merck
14.3.4 Novartis
14.3.5 Johnson & Johnson
14.3.6 Sanofi
14.3.7 GlaxoSmithKline
14.3.8 Amgen
14.3.9 AbbVie
14.3.10 Boehringer Ingelheim
14.3.11 AstraZeneca
14.3.12 Immatics Biotechnologies
